Clinical Trials Browser

Terminated × Alpelisib × Clear all

Triple Negative Breast Neoplasms

NCT04729387 2026-03-13

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase 3 Terminated

358 enrolled

Gynecologic

Ovarian Neoplasms

NCT04967248 2025-12-04

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

Terminated

4 enrolled

Breast

Breast Neoplasms

NCT03284957 2025-11-24

AMEERA-1

Phase 1/2 Terminated

136 enrolled 60 charts

Breast

Breast Neoplasms

NCT04216472 2025-09-30

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Phase 2 Terminated

6 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04899349 2024-10-09

EPIK-B4

Phase 2 Terminated

2 enrolled 8 charts

Breast

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

NCT05966584 2024-08-29

A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

Phase 2 Terminated

1 enrolled 5 charts

Breast

Breast Neoplasms, Exanthema

NCT04862143 2024-06-20

TELEPIK

Phase 2 Terminated

2 enrolled 10 charts

Breast

Advanced Breast Cancer

NCT03601507 2024-04-17

Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer

Phase 2 Terminated

9 enrolled 10 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04801966 2023-05-10

TAILOR

Phase NA Terminated

3 enrolled

Tumor-Agnostic

Neoplasms

NCT03386162 2022-11-28

SAFIR-PI3K

Phase 2 Terminated

31 enrolled

Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT02734615 2022-08-01

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Phase 1 Terminated

199 enrolled

Breast

Advanced or Metastatic ER+ Breast Cancer

NCT02550743 2021-03-12

BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study

Phase 1 Terminated

7 enrolled 7 charts

Gastrointestinal

Neoplasm Metastasis, Rectal Neoplasms

NCT01602315 2020-12-29

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1/2 Terminated

179 enrolled 38 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Hereditary Sensory and Autonomic Neuropathies

NCT02620839 2020-01-10

Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies

Phase 1 Terminated

28 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT01708161 2018-09-13

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

Phase 1/2 Terminated

47 enrolled 23 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

Clinical Trials

EPIK-B3

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

AMEERA-1

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

EPIK-B4

A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

TELEPIK

Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer

TAILOR

SAFIR-PI3K

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors